Literature DB >> 18226564

Elevated plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture.

W R W Wilson1, M Anderton, E C Choke, J Dawson, I M Loftus, M M Thompson.   

Abstract

BACKGROUND: The role of matrix metalloproteinases (MMPs) in abdominal aortic aneurysm (AAA) formation is well established. However the changes in plasma MMP levels with AAA rupture have not been reported. The aim of this study was to determine circulating levels of MMPs in non-ruptured and ruptured AAA immediately prior to open repair.
METHODS: Concentrations of MMPs and their endogenous tissue inhibitors (TIMPs) were quantified using ELISA in pre-operative plasma samples from non-ruptured and ruptured AAA.
RESULTS: MMP1 and MMP9 were elevated in the plasma of ruptured AAA versus non-ruptured AAA. A four-fold elevation in pre-operative plasma MMP9 was associated with non-survival at 30 days from rupture surgery compared with those surviving for greater than 30 days.
CONCLUSION: In conclusion, these findings support the role of MMPs in AAA pathogenesis. Elevation of MMP9 was associated with ruptured aneurysm related 30-day mortality and may represent a survival indicator in this group.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226564     DOI: 10.1016/j.ejvs.2007.12.004

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  31 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

3.  Temporal regulation of venous extracellular matrix components during arteriovenous fistula maturation.

Authors:  Michael R Hall; Kota Yamamoto; Clinton D Protack; Masayuki Tsuneki; Go Kuwahara; Roland Assi; Kirstyn E Brownson; Hualong Bai; Joseph A Madri; Alan Dardik
Journal:  J Vasc Access       Date:  2014-09-08       Impact factor: 2.283

Review 4.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 5.  Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms.

Authors:  Yanwen Qin; Xu Cao; Yaoguo Yang; Guo-Ping Shi
Journal:  Future Cardiol       Date:  2013-01

6.  Increased 18F-FDG uptake is predictive of rupture in a novel rat abdominal aortic aneurysm rupture model.

Authors:  Sean J English; Morand R Piert; Jose A Diaz; David Gordon; Abhijit Ghosh; Louis G DʼAlecy; Steven E Whitesall; Ashish K Sharma; Elise P DeRoo; Tessa Watt; Gang Su; Peter K Henke; Jonathan L Eliason; Gorav Ailawadi; Gilbert R Upchurch
Journal:  Ann Surg       Date:  2015-02       Impact factor: 12.969

7.  Hyperhomocysteinemia during aortic aneurysm, a plausible role of epigenetics.

Authors:  Nithya Narayanan; Neetu Tyagi; Amy Shah; Sebastian Pagni; Suresh C Tyagi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-03-08

Review 8.  Circulating markers of abdominal aortic aneurysm presence and progression.

Authors:  Jonathan Golledge; Philip S Tsao; Ronald L Dalman; Paul E Norman
Journal:  Circulation       Date:  2008-12-02       Impact factor: 29.690

9.  Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease.

Authors:  John S Ikonomidis; Charlotte R Ivey; Jason B Wheeler; Adam W Akerman; Allison Rice; Risha K Patel; Robert E Stroud; Asad A Shah; Chad G Hughes; Giovanni Ferrari; Rupak Mukherjee; Jeffrey A Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2013-01-11       Impact factor: 5.209

10.  Polymorphisms of the matrix metalloproteinase 9 gene and abdominal aortic aneurysm.

Authors:  L Smallwood; R Allcock; F van Bockxmeer; N Warrington; L J Palmer; B Iacopetta; J Golledge; P E Norman
Journal:  Br J Surg       Date:  2008-10       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.